XFOR X4 Pharmaceuticals, Inc.

X4 is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. X4ís pipeline is comprised of first-in-class, oral, small molecule antagonists of chemokine receptor CXCR4, which have the potential to treat a broad range of rare diseases, including primary immunodeficiencies, or PIs, and cancer. PIs are a group of more than 250 rare, chronic disorders in which flaws in the immune system cause increased susceptibility to infections and, in some cases, increased risk of cancers. Within this broad disease classification, a number of PIs are attributed to the improper trafficking of immune cells related to the CXCR4 receptor and its ligand CXCL12. X4ís lead product candidate, X4P-001, is in clinical development in patients with Warts, Hypogammaglobulinemia, Infections, and Myelokathexis, or WHIM syndrome, a PI that is a genetic rare disease.

$9.02
As of 04/09/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  11/16/2017
Outstanding shares:  17,384,478
Average volume:  138,184
Market cap:   $156,807,992
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    98420X103
ISIN:        US98420X1037
Sedol:      BFY8WQ4
Valuation   (See tab for details)
PE ratio:   -14.08
PB ratio:   2.02
PS ratio:   52.27
Return on equity:   -85.35%
Net income %:   -2,071.03%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy